126 Chapter 4 Table 1. Baseline characteristics Total group N = 105 Age median (IQR) 5.4 (4.1-8.9) Sex n (%) Boy 64 (61) Girl 41 (39) Week maintenance median (IQR) 34 (22-43) Asparaginase during study n (%) No 93 (88.6) Yes 12 (11.4) Type ALL1 n (%) B-cell ALL 93 (88.6) T-cell ALL 11 (10.5) CNS involvement2 n (%) No 85 (81) Yes 20 (19) 1 One patient with BPDCN 2 Patients with CNS involvement (defined as CNS-3 or other CNS manifestations at diagnosis, or TLP+) receive 2 additional intrathecal therapy administrations and are considered as “CNS involvement yes”. MRG patients without CNS involvement receive 13 intrathecal administrations, with CNS involvement 15. 0 10 20 30 40 0 10 20 30 40 SDQ Total Difficulties T1 T2 40 60 80 100 40 60 80 100 SDSC Total Score T1 T2 Figure 3. SDQ and SDSC scores at T1 and T2 SDQ (left) and SDSC (right) scores before (T1) and after (T2) a 5-day dexamethasone course. Each dot depicts one patient. Overall, the SDQ and SDSC scores rise between T1 and T2. Abbreviations: SDQ: strengths and difficulties questionnaire, SDSC: sleep disturbance scale for children
RkJQdWJsaXNoZXIy MTk4NDMw